Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

AI Model Uses Pretreatment CT Scans to Predict Immunotherapy-Related Pneumonitis Risk

By HospiMedica International staff writers
Posted on 26 Sep 2026

Pneumonitis is a potentially life-threatening form of lung inflammation that affects about 10% of patients with lung cancer receiving immunotherapy. More...

Because it can be difficult to predict before symptoms develop, clinicians may have limited ability to tailor monitoring to an individual patient’s risk. Current assessments based on clinical factors and imaging review do not fully capture this risk. Researchers have now developed an artificial intelligence model that identifies patients at increased risk before treatment begins.

Researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) developed the Checkpoint-Inhibitor Pneumonitis Hazard EstimatoR (CIPHER) to analyze routine pretreatment chest computed tomography (CT) scans. The model first learned to recognize patterns in lung tissue rather than learning directly from confirmed pneumonitis cases. Researchers then assessed whether those patterns were associated with pneumonitis after immunotherapy.

CIPHER was trained on more than 590,000 CT image slices from 2,500 patients with lung cancer. Researchers tested it using pretreatment scans from 347 patients with non-small cell lung cancer treated at UT MD Anderson and validated it in an independent external dataset. The model achieved an area under the curve of approximately 0.83 in both cohorts, outperforming conventional clinical-factor models and radiomics approaches. 

Performance remained strong across differences in patient populations, scanners and imaging protocols. Predictions remained significant after accounting for age, smoking history, tumor histology and prior thoracic radiation exposure. Patients classified as high-risk also tended to develop pneumonitis sooner after starting immunotherapy. 

Published in the Journal for ImmunoTherapy of Cancer on September 18, 2026, the findings require larger, more diverse prospective studies before clinical integration can be determined. Researchers also plan to examine performance in other cancer types and whether additional biomarkers improve prediction. 

“What makes this approach particularly interesting is that it was not designed to look for pneumonitis itself. Instead, the model learned patterns within lung tissue and identified subtle abnormalities associated with future risk. That suggests routine imaging may contain much more information about treatment toxicity than we previously recognized,” said Jia Wu, Ph.D., associate professor of Imaging Physics and Thoracic/Head and Neck Medical Oncology at UT MD Anderson. 

Related Links
UT MD Anderson


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Gas Analyzer
GE SAM
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.